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Abstract
Background: Herpes zoster (HZ), also known as shingles, is a painful and commonly occurring condition in the
United States. In spite of a universally recommended vaccine for use in immunocompetent adults aged 60 years
and older, HZ continues to impact the American public, and a better understanding of its current incidence is
needed. The objective of the current study is to estimate the overall and age- and gender-specific incidence rates
(IRs) of HZ among an immunocompetent US population in 2011 following availability of a vaccine.
Methods: Claims data from the Truven Health MarketScan® Research databases between 01/01/2011 and 12/31/2011
were extracted. Immunocompetent adult patients, enrolled as of January 1, 2011 were analyzed. The denominator was
defined as eligible subjects who were immunocompetent, had no evidence of zoster vaccination, and no diagnosis of
HZ (International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 053.xx) in the 90 days
prior to January 1, 2011. Subjects contributed person-days to the denominator until the occurrence of one of the
following events: end of continuous enrollment in the database, a claim for zoster vaccination, diagnosis of HZ or end
of the observation period (December 31, 2011). The numerator was defined as enrollees within the denominator file
exhibiting evidence of HZ. Annual IRs were calculated for the entire population in the database as well as by gender
and age group; standardized IRs were also produced using the 2010 US Census data.
Results: The overall annual IR of HZ across all ages was 4.47 per 1000 person-years (95 % confidence interval
[CI]: 4.44–4.50) which monotonically increased with age from 0.86 (95 % CI: 0.84–0.88) for those aged ≤19 to
12.78 (95 % CI: 12.49–13.07) for patients ≥80 years. The IR was 8.46 (95 % CI: 8.39–8.52) among adults ≥50 years
and 10.46 (95 % CI: 10.35–10.56) among those aged ≥60 years. Women compared to men had higher HZ
incidence (5.25, 95 % CI: 5.21–5.29 vs. 3.66, 95 % CI: 3.62–3.69) and this was seen across all age groups. When adjusted
for age and gender using 2010 US Census data, the annual IR was 4.63 per 1000 person-years (95 % CI: 4.61–4.66).
Conclusions: Despite the availability of a vaccine, HZ remains common among immunocompetent adults in the US
with incidence rates of HZ observed to increase with age and be higher in women than men.
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Background
Herpes zoster (HZ), or shingles, is caused by reactivation
of the varicella zoster virus (VZV) and mainly affects the
elderly population [1–3]. In the United States, over 99 %
of adults have serological evidence of VZV infection and
are susceptible to HZ [4], and the individual lifetime risk
of HZ is approximately 30 % [5]. It is estimated that ap-
proximately 1 million new cases of HZ are diagnosed
each year. While susceptibility to HZ increases with ad-
vancing age, the rate of incidence significantly increases
among patients aged >50 years, with a drastic rise in the
rate thereafter [2, 6]. The incidence rate of HZ ranged
between three and five per 1,000 person-years from prior
studies in the US and other countries, depending on the
population studied and immunocompetency of subjects
[5, 7–10]. However, estimates are prior to the introduc-
tion of a zoster vaccine in the United States.
Zostavax®, a live attenuated zoster vaccine approved in
the US for the prevention of HZ in immunocompetent
adults 50 years of age and older, is recommended by the
US Centers for Disease Control and Prevention’s Advis-
ory Committee on Immunization Practices (ACIP) for
use among immunocompetent adults aged 60 years and
older [11]. In a large randomized clinical trial, zoster
vaccine was shown to reduce the incidence of HZ by
51.3 % and the incidence of postherpetic neuralgia
(PHN) by 66.5 %, in immunocompetent adults 60 years
of age and older [6]. In addition, the Zostavax Efficacy
and Safety Trial (ZEST) demonstrated that zoster vac-
cine reduced the risk of HZ in adults 50 to 59 [12]. The
economic value of the zoster vaccine has been reviewed
and synthesized elsewhere [13].
In spite of vaccine availability, HZ continues to pose a
significant burden in the US. Despite ACIP recommen-
dations, in 2011 only 15.8 % of adults aged ≥60 years re-
ported ever receiving the zoster vaccine [14]. Previous
studies found that the incidence rate of HZ has changed
over time, and updated data on age-specific and sex-
specific incidence rates using a nationwide database is
important to understand the population at risk of HZ.
The objective of the current study is to estimate the
overall and age- and sex-specific incidence rates of HZ
among immunocompetent US adults in 2011 following
availability of a vaccine.
Methods
Data source
This retrospective, observational cohort study was con-
ducted using administrative claims data from two
Truven Health MarketScan® Research Databases – the
Commercial Claims and Encounters and the Medicare
Supplemental and Coordination of Benefits—for the
period January 1, 2011 through December 31, 2011. Both
databases include complete longitudinal records of
inpatient services, outpatient services, long-term care,
and prescription drug claims covered under a variety of
fee-for-service and managed care health plans, including
exclusive provider organizations, preferred provider or-
ganizations, point of service plans, indemnity plans, and
health maintenance organizations. The MarketScan Re-
search database records are de-identified and compliant
with US patient confidentiality requirements, including
the Health Insurance Portability and Accountability Act
1996. Permissions were not needed to utilize these data.
Since this study used only de-identified patient records
and did not involve the collection, use, or transmittal of
individually identifiable data, Institutional Review Board
approval was not necessary.
Patient selection
Patients with and without HZ (International Classification
of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] diagnosis code 053.xx), enrolled as of January 1,
2011, having no claims for HZ or evidence of receiving
shingles vaccination in the 90 days prior to January 1,
2011, and meeting criteria for immunocompetent status
were included. A series of selected ICD-9-CM diagnoses,
procedures and treatment criteria, informed by the Cen-
ters for Disease Control and Prevention [11] were used to
determine the immunocompetent status of each patient.
Patients were excluded if they had ICD-9-CM diagnosis or
procedure codes for hematologic malignancy, solid tumor
malignancy, human immunodeficiency virus, chronic
renal failure, nephrotic syndrome, and other select immu-
nocompromising conditions. Patients were also excluded
if they had evidence of organ transplantation, procedures
indicating injection or infusion of cancer chemotherapeu-
tic substance, immunotherapy as antineoplastic agent,
poisoning by antineoplastic and immunosuppressive
drugs, or treatment with chemotherapy, radiation therapy,
corticosteroids, tumor necrosis factor inhibitors, protease
inhibitors, reverse transcriptase inhibitors, azathioprine,
cyclosporine, or tacrolimus.
Annual incidence rate
The annual incidence rates of HZ were calculated for
the entire population observed in the database as well as
by gender and age group (<19, 20–29, 30–39, 40–49,
50–59, 60–69, 70–79, 80+). Standardized incidence rates
were also produced using the 2010 US Census data to
produce overall and gender-specific rates by age group
[15]. In addition, rates were reported for those aged ≥50
and ≥60 years.
Statistical analysis
Descriptive analyses were conducted to determine the
demographic characteristics of the study cohort. Annual
incidence rates of HZ in the immunocompetent were
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estimated by dividing the total unique number of incident
HZ patients observed in the reporting year by the total
number of person-years in the reporting year. The calcula-
tions for the denominator and numerator were performed
as described previously [16]. The denominator was de-
fined as eligible subjects who were immunocompetent,
had no evidence of shingles vaccination, and no diagnosis
of HZ in the 90 days prior to January 1, 2011. Subjects
contributed person-days to the denominator until the oc-
currence of one of the following events: end of continuous
enrollment in the database, a claim for zoster vaccine,
diagnosis of HZ, or end of the observation period (De-
cember 31, 2011). Rates of HZ were presented per 1,000
person-years, and the direct standardized rate and 95 %
confidence intervals were calculated by Chiang’s nor-
mal approximation to Poisson rate sums [17]. A p-value
of <0.05 was considered statistically significant.
Results
A total of 113,861 incident cases of HZ were observed in
the database during the study period. Demographic
characteristics of the study cohort are shown in Table 1.
The mean population age was 52 (standard deviation:
17.8) years, with the majority aged ≥50 years (60 %), and
females comprising 60 % of the study population. Over a
third of patients resided in the south region of the
United States (36 %) and the majority was covered by
commercial insurance (79.1 %) (Table 1).
The overall annual incidence rate of HZ, across all ages
of the study population, was 4.47 per 1,000 person-years
(95 % confidence interval [CI]: 4.44–4.50) with higher
rates observed among women than men (5.25, 95 % CI:
5.21–5.29 vs. 3.66, 95 % CI: 3.62–3.69), respectively)
across all age groups. The rate of HZ increased monoton-
ically with age, ranging from 0.86 (95 % CI: 0.84–0.88) for
those aged ≤19 to 12.78 (95 % CI: 12.49–13.07) for
immunocompetent HZ patients aged 80 and older (see
Additional file 1). When the raw annual incidence rates of
HZ across all ages were adjusted for age and sex using
2010 US Census data, the overall rate was 4.63 per 1,000
person-years (95 % CI: 4.61, 4.66), with higher rates ob-
served among women than men (5.52, 95 % CI: 5.45–5.53
vs. 3.66, 95 % CI: 3.62–3.79, respectively).
When incidence rates of HZ were examined for com-
bined cohorts across age groups (i.e. those aged 50 and
older and those 60 and older), the incidence rate in-
creased from 8.46 (95 % CI: 8.39–8.52) among adults
50 years and older to 10.46 (95 % CI: 10.35–10.56)
among those aged 60 years and older. Similarly, rates for
males and females followed a nearly identical trend,
increasing from 6.71 (95 % CI: 6.63–6.80) to 8.73 (95 %
CI: 8.60–8.87) in males and from 10.06 (95 % CI: 9.96–
10.15) to 12.00 (95 % CI: 11.85–12.16) in females (see
Additional file 1).
Discussion
The current study demonstrates that despite the avail-
ability of HZ vaccine, incidence of herpes zoster among
an insured population has not decreased. A total of
Table 1 Demographic Characteristics of Incident Herpes Zoster
Population
All HZ Patients Total Denominator
Demographic Characteristics N = 113, 861 N = 27,616,373
Mean age, year (SD) 52.0 (17.8) 36.9 (21.0)
Age Group, n (%)
<50 45,588 (40) 18,972,479 (69)
50–59 29,266 (26) 4,620,496 (17)
60–64 14,959 (13) 1,866,686 (7)
65–69 6,636 (6) 674,081 (2)
70–79 10,231 (9) 884,385 (3)
80+ 7,181, (6) 598,246 (2)
Gender, n (%)
Male 45,457 (40) 13,496,731 (49)
Female 68,404 (60) 14,119,642 (51)
Health Plan, n (%)
Comprehensive/Indemnity 13,128 (12) 1,366,332 (5)
EPO/PPO 62,100 (55) 15,751,867 (57)
POS/POS w/capitation 7,806 (7) 2,128,553 (8)
HMO 16,430 (14) 4,235,960 (15)
CDHP/HDHP 6,905 (6) 2,109,739 (8)
Missing/Unknown 7,492 (7) 2,023,922 (7)
Primary Insurance, n (%)
Commercial 89,495 (79) 25,416,170 (92)
Medicare 24,366 (21) 2,200,203 (8)
Geographic Region, n (%)
Northeast 20,268 (18) 5,113,594 (19)
North Central 29,490 (26) 6,765,658 (25)
South 40,575 (36) 9,976,789 (36)
West 22,653 (20) 5,471,074 (20)
Unknown Region 875 (1) 289,258 (1)
Employee classification, n (%)
Employee, salaried 11,441 (10) 2,246,437 (8)
Employee, hourly 14,944 (13) 2,524,118 (9)
Employee, unknown 48,419 (43) 9,006,547 (33)
Spouse or dependent 39,057 (34) 13,839,271 (50)
Employee Relationship, n (%)
Employee 74,804 (66) 13,777,102 (50)
Spouse 30,900 (27) 5,415,157 (20)
Child/Other 8,157 (7) 8,424,114 (31)
HMO health maintenance organization, POS point-of-service, PPO/EPO
preferred provider organization/exclusive provider organization, CDHP/HDHP
consumer-driven health plan/high-deductible health plan
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113,871 immunocompetent patients with HZ were ana-
lyzed in this retrospective study. The overall annual HZ
incidence rate for the year 2011 was 4.47 per 1,000
person-years in our dataset and 4.63 per 1,000 person-
years when standardized for age and sex using 2010 US
Census data.
Understanding the age-specific incidence rate of HZ is
important as they represent the target population for
zoster vaccine. Consistent with other studies, the risk of
HZ increased with advancing age. The age-specific inci-
dence ranged from 0.86 per 1000 person-years in indi-
viduals <19 years of age to 12.78 per 1000 person-years
among those 80 years of age and older, and increased
rapidly after 50 years of age. The age-related increase in
the incidence may be closely linked to an age-dependent
decline in VZV-specific cell-mediated immunity. How-
ever, the U.S. Food and Drug Administration approval of
the zoster vaccine for use in adults over 50 years of age
contrasts recommendations from the ACIP which rec-
ommends vaccination of adults 60 years and older [11].
A substantial public health burden of HZ also occurs in
adults 50 to 59 years of age, most of whom are working
adults. In our study, over 25 % of HZ occurred in adults
50 to 59 years of age and another 34 % occurred in
adults >60 years of age in the US.
Our age- and sex-standardized estimated rate of 4.6
cases per 1,000 person-years among immunocompetent
patients is comparable to recent studies using administra-
tive data in the US. Previously, reported rates were 4.8 per
1,000 person-years from the general population that in-
cludes immunocompromised individuals in 2005–09 [8]
and 4.4 per 1,000 person-years in 2006 [9]. Similarly, Yawn
and colleagues reported incidence rates of 3.6 per 1,000
person-years in a population-based study in Minnesota
that incorporated medical record review from 1996 to
2001 [5]. Another study which utilized the MarketScan
databases, reported an incidence rate of HZ of 3.2 per
1,000 person-years in years 2000–2001 [7]. Studies con-
ducted more than 20 years ago in the US showed even
lower rates: 2.2 in years 1990–1992 [18] and 1.3 per 1,000
person-years in years 1945–1959 [19]. This trend over
time is consistent with most studies that examined tem-
poral trends in the US and six other countries across the
globe [2, 9, 20–23].
We observed a higher incidence rate of HZ in women
than men (5.2 versus 3.7 per 1,000 person-years, respect-
ively) across all age groups. Although some studies
found no difference, the majority of prior studies from
across countries also found that women have a greater
risk of HZ than men [1, 5, 20–22, 24–27]. This differ-
ence may be partly due to differences in health seeking
behavior; however, the difference may also be due to bio-
logical factors. In the Shingles Prevention Study clinical
trial where participants were actively followed up and
cases were laboratory-confirmed, women had higher in-
cidence rates of HZ than men in the placebo group
(11.79 versus 10.65 per 1,000 person-years, respectively)
[6]. It is plausible that there may be immunological or
hormonal differences between women and men in re-
sponse to reactivation of latent virus infection.
As with all retrospective studies, the current investiga-
tion has potential limitations. First, the study was limited
to only those individuals with commercial health cover-
age or private Medicare supplemental coverage in the
US; therefore, results may not be generalizable to HZ
patients with other insurance or without coverage or
those living outside the US. Second, the potential for
misclassification of HZ, covariates, or study outcomes
was potentially present as patients were identified
through administrative claims data which are subject to
data coding limitations and data entry error as opposed
to medical records. However, previous studies found that
the positive predictive value of ICD-9-CM codes for HZ
in administrative claims data is relatively high, ranging
from 84 to 94 % [18, 28, 29]. Third, since the zoster vac-
cine was approved in 2008 and this study only looked
back 90 days prior to January 1, 2011 for evidence of
vaccination, it is possible that both vaccinated and un-
vaccinated patients are included in the calculation.
Fourth, this study used only one year of data to calculate
incidence and may not represent the actual incidence if
by any chance there were more or less cases reported in
2011. This study offers advantages, including the most
updated estimate based on a nationwide administrative
database in the US In addition, this study is based on a
substantial number of datasets evaluated from two large
administrative databases which allowed us to estimate
the age- and sex-specific incidence rates in the immuno-
competent population.
Conclusions
Despite the availability of a vaccine, herpes zoster re-
mains common among immunocompetent adults with
incidence rates of HZ observed to increase with age and
be higher in women than men. A significant focus on
how to reduce the risk of HZ, e.g. improving vaccine ac-
cess, should be adopted by health care providers.
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